DiSCoVERing innovative therapies for rare tumors: Combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets

Clinical Cancer Research

Volumn 22, Issue 15, 2016, Pages 3903-3914

  Hanaford, Allison R ^a   Archer, Tenley C ^b,c   Price, Antoinette ^a   Kahlert, Ulf D ^d   Maciaczyk, Jarek ^d   Nikkhah, Guido ^e   Kim, Jong Wook ^b,f   Ehrenberger, Tobias ^b,g   Clemons, Paul A ^b   Dančík, Vlado ^b   Seashore Ludlow, Brinton ^b   Viswanathan, Vasanthi ^b   Stewart, Michelle L ^b   Rees, Matthew G ^b   Shamji, Alykhan ^b   Schreiber, Stuart ^b,h,i   Fraenkel, Ernest ^b,g   Pomeroy, Scott L ^b,c   Mesirov, Jill P ^b,j,k   Tamayo, Pablo ^b,j,k   Eberhart Eric Raabe, Charles G H ^a,l   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e University Hospital   (Germany)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g USA   (United States)

^h HARVARD UNIVERSITY   (United States)

ⁱ HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^j UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^k UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^l JOHNS HOPKINS HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD133 ANTIGEN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; MYC PROTEIN; NESTIN; PALBOCICLIB; PROTEIN KINASE B; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR SOX2; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; DISEASE MODEL; DRUG SENSITIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BIOLOGY; CEREBELLUM TUMOR; COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOUSE; NEURAL STEM CELL; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BIOMARKERS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEDULLOBLASTOMA; MICE; MODELS, BIOLOGICAL; NEURAL STEM CELLS; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; PYRIDINES; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84982743491     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-3011     Document Type: Article

References (60)

1. Silva PB, Rodini CO, Kaid C, Nakahata AM, Pereira MC, Matushita H, et al. Establishment of a novel human medulloblastoma cell line characterized by highly aggressive stem-like cells. Cytotechnology . 2015 Sep 10. [Epub ahead of print].
2. Hughes P, Marshall D, Reid Y, Parkes H, Gelber C. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? Biotechniques 2007;43:575.
3. Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol 2012; 14:574-83.
4. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 2002;16:2045-57.
5. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012;8:340-51.
6. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006; 66:673-81.
7. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al. Outcome prediction in pediatric medulloblastoma based on DNA copynumber aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009;27:1627-36.
8. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63: 441-9.
9. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29:1408-14.
10. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international metaanalysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123:473-84.
11. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123:465-72.
12. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011;29: 1424-30.
13. Tamayo P, Cho YJ, Tsherniak A, Greulich H, Ambrogio L, Schouten-van Meeteren N, et al. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol 2011;29:1415-23.
14. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 2012;21:155-67.
15. Kawauchi D, Robinson G, Uziel T, Gibson P, Rehg J, Gao C, et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 2012;21:168-80.
16. Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 2014;20:912-25.
17. Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell 2015;27:72-84.
18. Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 1990;50:2347-50.
19. Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev 2010;24:1059-72.
20. Poschl J, Stark S, Neumann P, Grobner S, Kawauchi D, Jones DT, et al. Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. Acta Neuropathol 2014;128:123-36.
21. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011;331: 435-9.
22. Lopez WO, Nikkhah G, Kahlert UD, Maciaczyk D, Bogiel T, Moellers S, et al. Clinical neurotransplantation protocol for Huntington's and Parkinson's disease. Restor Neurol Neurosci 2013;31:579-95.
23. Mao XG, Hutt-Cabezas M, Orr BA, Weingart M, Taylor I, Rajan AK, et al. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget 2013;4:1050-64.
24. Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, et al. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res 2011;17: 3590-9.
25. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006;7:3.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
27. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007;23:3251-3.
28. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
29. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013;41: D955-61.
30. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
31. Seashore-Ludlow B, Rees MG, Cheah JH, Cokol M, Price EV, Coletti ME, et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov 2015;5:1210-23.
32. Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res 2013;73:6289-98.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57: 289-300.
34. Weingart MF, Roth JJ, Hutt-Cabezas M, Busse TM, Kaur H, Price A, et al. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget 2015;6:3165-77.
35. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
36. Barton KL, Misuraca K, Cordero F, Dobrikova E, Min HD, Gromeier M, et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS ONE 2013;8:e77639.
37. Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-38.
38. Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res 2008;68:5519-23.
39. Frank AJ, Hernan R, Hollander A, Lindsey JC, Lusher ME, Fuller CE, et al. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/ cell anaplastic medulloblastoma. Brain Res Mol Brain Res 2004;121: 137-40.
40. Eberhart CG, Chaudhry A, Daniel RW, Khaki L, Shah KV, Gravitt PE. Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer 2005;5:19.
41. Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013;31:2927-35.
42. Mumert M, Dubuc A, Wu X, Northcott PA, Chin SS, Pedone CA, et al. Functional genomics identifiesdriversof medulloblastoma dissemination. Cancer Res 2012;72:4944-53.
43. Fan X, Wang Y, Kratz J, Brat DJ, Robitaille Y, Moghrabi A, et al. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol 2003;162:1763-9.
44. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LAJr, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013;110:6021-6.
45. Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 2013;14:1200-7.
46. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, et al. Growth inhibition with reversible cell-cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736-40.
47. Stanetty P, Hattinger G, Schnurch M, Mihovilovic MD. Novel and efficient access to phenylamino-pyrimidine type protein kinase C inhibitors utilizing a Negishi cross-coupling strategy. J Org Chem 2005;70: 5215-20.
48. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999;19:4672-83.
49. Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, et al. Pleiotropic effects of miR-18396182 converge to regulate cell survival, proliferation, and migration in medulloblastoma. Acta Neuropathol 2012;123:539-52.
50. Bretones G, Delgado MD, Leon J. Myc and cell cycle control. Biochim Biophys Acta 2015;1849:506-16.
51. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007; 13:820-7.
52. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010;12:54-9.
53. Faria CC, Agnihotri S, Mack SC, Golbourn BJ, Diaz RJ, Olsen S, et al. Identification of alsterpaullone as a novel small-molecule inhibitor to target group 3 medulloblastoma. Oncotarget 2015;6:21718-29.
54. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-19.
55. Whiteway SL, Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, et al. Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. J Neurooncol 2013;111:113-21.
56. Morfouace M, Shelat A, Jacus M, Freeman BBIII, Turner D, Robinson S, et al. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell 2014;25:516-29.
57. Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem 2012;287: 29075-87.
58. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
59. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 2006;66: 7661-7.
60. Yang C, Boyson CA, Di Liberto M, Huang X, Hannah J, Dorn DC, et al. CDK4/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity. Cancer Res 2015;75:1838-45.